Investment Analysts’ Weekly Ratings Updates for Equillium (EQ)

A number of firms have modified their ratings and price targets on shares of Equillium (NASDAQ: EQ) recently:

• 5/28/2026 – Equillium had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $7.00 price target on the stock.
• 5/28/2026 – Equillium was given a new $5.00 price target by Stifel Nicolaus.
• 5/28/2026 – Equillium had its “buy” rating reaffirmed by Roth Mkm. They now have a $12.00 price target on the stock.
• 5/28/2026 – Equillium was upgraded by Leerink Partners from “market perform” to “outperform”. They now have a $6.00 price target on the stock, up from $1.00.
• 5/16/2026 – Equillium was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/23/2026 – Equillium is now covered by Oppenheimer Holdings, Inc.. They set an “outperform” rating and a $7.00 price target on the stock.
• 4/17/2026 – Equillium had its “buy” rating reaffirmed by Roth Mkm. They now have a $12.00 price target on the stock.
• 4/16/2026 – Equillium is now covered by B. Riley Financial, Inc.. They set a “buy” rating and a $6.00 price target on the stock.
• 4/13/2026 – Equillium is now covered by Raymond James Financial, Inc.. They set a “strong-buy” rating and a $6.00 price target on the stock.

Insider Activity

In other news, insider Stephen Connelly sold 200,000 shares of the firm’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $3.16, for a total transaction of $632,000.00. Following the transaction, the insider directly owned 793,000 shares of the company’s stock, valued at approximately $2,505,880. This trade represents a 20.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Penny Tom sold 65,000 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $2.95, for a total value of $191,750.00. Following the transaction, the insider directly owned 65,000 shares in the company, valued at $191,750. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 526,704 shares of company stock valued at $1,525,678. 17.84% of the stock is currently owned by insiders.

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.